| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Signal transducer CD24, Small cell lung carcinoma cluster 4 antigen, CD24, CD24, CD24A |
| Entrez GeneID | 100133941 |
| WB Predicted band size | 8.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CD24 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 17-38 amino acids from the Central region of human CD24. |
+ +
以下是关于CD24抗体的3篇代表性文献的简要整理(基于公开研究，具体信息建议通过学术数据库验证)：
---
1. **标题**: *CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy*
**作者**: Barkal, A.A. et al.
**摘要**: 该研究发表于*Nature*(2019年)，揭示了CD24作为肿瘤细胞表面“别吃我”信号，通过与巨噬细胞上的Siglec-10结合抑制吞噬作用。抗CD24抗体可阻断此通路，增强巨噬细胞对卵巢癌和三阴性乳腺癌细胞的清除，为免疫治疗提供新靶点。
2. **标题**: *CD24 is a new cancer stem cell biomarker and a potential therapeutic target in colorectal cancer*
**作者**: Sagiv, E. et al.
**摘要**: 发表于*Oncotarget*(2016年)，研究发现CD24在结肠癌干细胞中高表达，与肿瘤侵袭和转移相关。抗CD24抗体通过靶向清除CD24+细胞显著抑制小鼠模型中肿瘤生长，提示其作为结直肠癌治疗的潜力。
3. **标题**: *CD24 expression is a marker for predicting clinical outcome in patients with ovarian cancer*
**作者**: Kristiansen, G. et al.
**摘要**: 发表于*Modern Pathology*(2010年)，通过对卵巢癌组织样本的分析，发现CD24高表达与患者不良预后相关。研究建议抗CD24抗体可能用于靶向治疗或联合化疗改善预后。
---
**注**：文献检索建议通过PubMed或Web of Science等平台核实详细信息。如需实验应用类文献，可进一步关注近期针对CD24抗体药物开发的临床前研究。
CD24. a small glycosylphosphatidylinositol (GPI)-anchored cell surface protein, functions as a “don’t eat me” signal by interacting with Siglec-10 on immune cells to suppress phagocytosis and immune activation. It is highly expressed in various cancers (e.g., breast, ovarian, and lung cancers) and implicated in tumor immune evasion, metastasis, and poor prognosis. CD24 is also involved in regulating stem cell properties and inflammatory responses.
CD24 antibodies are tools designed to target this protein for research, diagnostic, or therapeutic purposes. In cancer research, anti-CD24 antibodies are explored to block CD24-Siglec-10 interactions, thereby enhancing anti-tumor immunity by promoting macrophage-mediated phagocytosis of cancer cells. They also aid in studying CD24’s role in tumor biology and stem cell regulation. Clinically, CD24-targeting antibodies (e.g., those in preclinical development) hold potential as immunotherapies, either alone or combined with checkpoint inhibitors. Additionally, CD24 antibodies are used diagnostically to assess CD24 expression levels in tumors, correlating with aggressiveness or resistance to therapy.
Recent studies highlight CD24 as a promising biomarker and therapeutic target, particularly in cancers resistant to existing “don’t eat me” therapies (e.g., anti-CD47). Challenges include optimizing antibody specificity and minimizing off-target effects due to CD24’s broad expression in healthy tissues. Ongoing research aims to refine CD24 antibody applications in precision oncology.
×
